| 溶解性 | 25°C: DMSO |
| 存贮条件 | 储存温度-20°C |
| 生化机理 | Description:IC50 Value: N/ABalaglitazone (DRF-2593) is a novel partial agonist of PPAR-gamma (γ), which is developed by Dr. Reddy's laboratories India. Balaglitazone is a second generation peroxisome proliferator-activated receptor (PPAR) gamma agonist with only partial agonistic properties.in vitro: The Rs for the separations were 3.5 for balaglitazone enantiomers, 3.5 for pioglitazone enantiomers, and 3.7 for rosiglitazone. The squared correlation coefficients (r2) were found to be 0.999 for all three compounds [1].in vivo: Balaglitazone treated groups shown significantly reduce of HbA1c (%), FSG (mmol/L), postprandial glucose as comparison to pioglitazone. Balaglitazone 10 mg and 20 mg show the similar magnitudes of the effects which comparable to the effects seen in the pioglitazone 45 mg group. The incidence of fluid retention and fat accumulation fewer than those observed with pioglitazone 45 mg [2]. Sixty male dio induced obese |
| 别名 | DRF-2593;NN-2344;DRF2593;NN2344;DRF 2593;NN 2344;巴格列酮;DRF-2593;NN-2344;DRF2593;NN2344;DRF 2593;NN 2344;5-[[4-[[3-Methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl]methyl]thiazolidine-2,4-dione |
巴格列酮
Balaglitazone （订货以英文为准）
编号：B125827
CAS号：199113-98-9
分子式：C20H17N3O4S
分子量：395.43
| 产品名称 | Balaglitazone |
| 中文名称 | 巴格列酮 |
| CAS号 | 199113-98-9 |
| 分子式（M.F.） | C20H17N3O4S |
| 分子量（M.W.） | 395.43 |
| 储存条件 | -20°C储存 |
搜索质检报告(COA)
搜索MSDS
相关产品
党沛 
